The efficacy of metformin in counteracting olanzapine-induced hyperprolactinemia: an open-label prospective study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Open-label prospective study demonstrates metformin reduces prolactin levels in schizophrenia patients, suggesting metabolic benefits.

Metformin significantly decreased prolactin levels after eight weeks of treatment.
Prolactin levels dropped from 39.7 ng/mL to 35.7 ng/mL, indicating a notable reduction (p = 0.005).
Prospective analysis involved 31 schizophrenia patients receiving metformin at 1500 mg/day for eight weeks.
The findings suggest metformin may mitigate antipsychotic-induced hyperprolactinemia and improve metabolic health.

Goh et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark